ArticleScientific reports2021

A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world.

Dong Hyek Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.